Vaxcyte, Inc. (NASDAQ:PCVX) Stock Position Raised by Acuta Capital Partners LLC

Acuta Capital Partners LLC raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 22.6% during the third quarter, HoldingsChannel.com reports. The firm owned 135,400 shares of the company’s stock after buying an additional 25,000 shares during the period. Vaxcyte makes up about 12.5% of Acuta Capital Partners LLC’s portfolio, making the stock its biggest holding. Acuta Capital Partners LLC’s holdings in Vaxcyte were worth $15,472,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FORA Capital LLC bought a new position in Vaxcyte during the third quarter worth $3,928,000. MetLife Investment Management LLC raised its holdings in shares of Vaxcyte by 7.7% during the third quarter. MetLife Investment Management LLC now owns 67,833 shares of the company’s stock worth $7,751,000 after purchasing an additional 4,866 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Vaxcyte by 19.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 157,024 shares of the company’s stock worth $17,943,000 after buying an additional 25,275 shares during the last quarter. Bank of Montreal Can acquired a new position in shares of Vaxcyte in the 3rd quarter valued at about $3,104,000. Finally, Algert Global LLC grew its position in shares of Vaxcyte by 13.1% during the 3rd quarter. Algert Global LLC now owns 39,292 shares of the company’s stock valued at $4,490,000 after buying an additional 4,540 shares during the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Vaxcyte

In other news, SVP Elvia Cowan sold 5,000 shares of Vaxcyte stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total transaction of $538,350.00. Following the transaction, the senior vice president now directly owns 12,723 shares in the company, valued at approximately $1,369,885.41. This trade represents a 28.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Grant Pickering sold 2,366 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total value of $245,803.74. Following the completion of the sale, the chief executive officer now owns 137,398 shares of the company’s stock, valued at approximately $14,274,278.22. This trade represents a 1.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 102,464 shares of company stock worth $11,455,576 over the last quarter. 3.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Bank of America raised their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Leerink Partners boosted their price objective on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Needham & Company LLC restated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, November 6th. Jefferies Financial Group raised their target price on Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Stock Up 2.8 %

Shares of NASDAQ PCVX opened at $93.98 on Thursday. The firm’s 50-day simple moving average is $106.48 and its 200 day simple moving average is $89.97. The stock has a market cap of $11.71 billion, a P/E ratio of -20.43 and a beta of 1.01. Vaxcyte, Inc. has a fifty-two week low of $48.81 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the company earned ($0.91) EPS. On average, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.